Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology.
Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released.
TESARO Inc. announced the presentation of maturing data from the TOPACIO trial of Zejula (niraparib) in combination with Keytruda (pembrolizuma) during a plenary session at the 2018 Society for Gynecologic Oncology Annual Meeting on Women's Cancer in New Orleans.
A retrospective analysis of the phase III NOVA trial identified two baseline characteristics, patient body weight less than 170 pounds (77 kilograms) or platelet count of <150,000/µL to be significant factors for grade III or IV thrombocytopenia.
Array BioPharma Inc. published the results of its phase III COLUMBUS trial for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma were published in The Lancet Oncology.
AVEO Oncology has published the long-term follow-up results from Study 902, where patients were treated with tivozanib (Fotvda) as second-line treatment in advanced renal cell carcinoma, in the European Journal of Cancer. The publication, titled “Efficacy of Tivozanib Treatment after Sorafenib in Patients with Advanced Renal Cell Carcinoma: Crossover of a Phase 3 Study”, was published online first and is available here.
Men who take the medication finasteride get a prostate cancer prevention benefit that can last 16 years—twice as long as previously recorded, according to SWOG clinical trial analysis published in the Journal of the National Cancer Institute.
Researchers at Emory University and Northwestern University developed artificial intelligence software that can predict the survival of patients diagnosed with glioma by examining data from tissue biopsies.
The American Society for Radiation Oncology issued a clinical guideline for the use of whole breast radiation therapy for breast cancer that expands the population of patients recommended to receive accelerated treatment known as hypofractionated therapy.
A newly-published study shows many remain at risk for later complications from chemotherapy or other treatments. The study in the Journal of the National Comprehensive Cancer Network confirms testicular cancer survivors are more likely to develop high blood pressure, high cholesterol, and obesity, which can significantly increase their risk of heart disease.
